MK-677

MK-677 is an oral ghrelin receptor agonist and growth hormone secretagogue that people run to drive GH/IGF-1, boost appetite, support muscle mass and recovery, and improve sleep quality, with 71 captured community reports showing 92.9% positive sentiment for GH/IGF-1 axis support and 88% for appetite stimulation. The typical protocol is 25 mg, though some use anywhere from 10–50 mg daily, taken pre-bed and run continuously. Around a quarter of participants withdrew across the registered trial program, a discontinuation rate at odds with the compound’s strong community sentiment.

MK-677

Research Evidence

Evidence shape

Moderate evidence overall — the strongest completed human trials anchor this rating — but the data are spread thin across five mapped indications, with single exploratory studies in NAFLD, cognitive aging, and fibromyalgia. Posted results from three distinct sponsors cover a combined twelve subjects, while one in four registered trials was withdrawn. Chronic Kidney Disease has no trial data behind it, and most indications rest on a single unreplicated study or animal work alone.

Depthhow much
4 registered trials
3 completed · 1 with posted results · combined n=12
Breadthhow many areas
5 indications mapped
3 thin / exploratory · 1 animal-only · 4 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 2
3 distinct sponsors · 25% withdrawal rate · AE table from NCT05364684
Breadth and depth10 rows captured
Human
direct clinical signal
4
Animal
translational support
2
In vitro
mechanistic support
4
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
bgpharmadrugs.to
--
25 mg
$15.00
$0.6/mg
2
Chemyo
US
10 mg
$9.99
$1/mg
3
Genx Peptides
US
50 mg
$74.00
$1.48/mg
4
Soma Chems
US
25 mg
$59.99
$2.4/mg
5
EU Peptide Shop
Europe
25 mg
$62.90
$2.52/mg
6
Moglabs
US
25 mg
$68.00
$2.72/mg

price offers can be sorted by column

1-6 of 17

Dosing & Protocol

How MK-677 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 3
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

3 completed trials identified; trial dosing not reliably extracted from registry data.

3 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 70 reports
Typical dose
No quantified dose captured for this tier.
Frequency
unspecified
Timing
unspecified
Route
oral
Cycle
unspecified

Anecdotal reports suggest typical doses of 10-30 mg daily, administered orally, with many users opting for continuous use. The primary benefits reported are related to GH/IGF-1 axis support and appetite increase. Some users do cycle off, but often due to individual response or extended duration of use.

1 source

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for MK-677, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.